Gain Historical Income Statement

GANX Stock

USD 1.70 0.13 7.10%

Historical analysis of Gain Therapeutics income statement accounts such as Depreciation And Amortization of 44.3 K or Interest Expense of 298.7 K can show how well Gain Therapeutics performed in making a profits. Evaluating Gain Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Gain Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Gain Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Gain Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gain Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.

About Gain Income Statement Analysis

Gain Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Gain Therapeutics shareholders. The income statement also shows Gain investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Gain Therapeutics Income Statement Chart

At this time, Gain Therapeutics' Tax Provision is fairly stable compared to the past year. Net Interest Income is likely to rise to about 579.3 K in 2024, whereas Depreciation And Amortization is likely to drop slightly above 44.3 K in 2024.

Tax Provision Selling General Administrative Total Revenue Other Operating Expenses

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Total Revenue

Total revenue comprises all receipts Gain Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Gain Therapeutics. It is also known as Gain Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Gain Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Gain Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gain Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.At this time, Gain Therapeutics' Tax Provision is fairly stable compared to the past year. Net Interest Income is likely to rise to about 579.3 K in 2024, whereas Depreciation And Amortization is likely to drop slightly above 44.3 K in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	15.5K	64.2K	78.1K	82.0K
Total Operating Expenses	14.0M	17.9M	22.3M	11.2M

Reconciled Depreciation Total Operating Expenses

Gain Therapeutics income statement Correlations

	Tax Provision	Net Interest Income	Depreciation And Amortization	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Cost Of Revenue	Interest Income	Non Operating Income Net Other	Selling And Marketing Expenses
Tax Provision		0.99	0.74	0.9	0.4	0.19	0.79	-0.9	-0.9	-0.9	0.79	-0.9	0.79	0.98	-0.9	0.66	-0.9	0.95	-0.65	0.9	0.86	-0.86
Net Interest Income	0.99		0.78	0.94	0.5	0.09	0.84	-0.94	-0.94	-0.94	0.85	-0.94	0.84	1.0	-0.94	0.66	-0.94	0.95	-0.59	0.88	0.83	-0.84
Depreciation And Amortization	0.74	0.78		0.74	0.49	0.06	0.78	-0.76	-0.76	-0.76	0.79	-0.76	0.78	0.77	-0.76	0.49	-0.76	0.75	-0.45	0.62	0.65	-0.49
Selling General Administrative	0.9	0.94	0.74		0.75	-0.22	0.94	-1.0	-1.0	-1.0	0.94	-1.0	0.94	0.96	-1.0	0.64	-1.0	0.89	-0.31	0.76	0.73	-0.73
Total Revenue	0.4	0.5	0.49	0.75		-0.65	0.76	-0.74	-0.74	-0.74	0.74	-0.74	0.76	0.56	-0.74	0.48	-0.74	0.5	0.26	0.19	0.15	-0.22
Gross Profit	0.19	0.09	0.06	-0.22	-0.65		-0.3	0.24	0.24	0.24	-0.31	0.24	-0.3	0.03	0.24	0.29	0.24	0.22	-0.82	0.12	0.12	-0.12
Other Operating Expenses	0.79	0.84	0.78	0.94	0.76	-0.3		-0.95	-0.95	-0.95	1.0	-0.95	1.0	0.87	-0.95	0.62	-0.95	0.81	-0.21	0.66	0.7	-0.5
Operating Income	-0.9	-0.94	-0.76	-1.0	-0.74	0.24	-0.95		1.0	1.0	-0.95	1.0	-0.95	-0.96	1.0	-0.61	1.0	-0.88	0.3	-0.78	-0.75	0.73
Net Income From Continuing Ops	-0.9	-0.94	-0.76	-1.0	-0.74	0.24	-0.95	1.0		1.0	-0.95	1.0	-0.95	-0.96	1.0	-0.6	1.0	-0.88	0.29	-0.78	-0.75	0.73
Ebit	-0.9	-0.94	-0.76	-1.0	-0.74	0.24	-0.95	1.0	1.0		-0.95	1.0	-0.95	-0.96	1.0	-0.61	1.0	-0.88	0.3	-0.78	-0.75	0.72
Research Development	0.79	0.85	0.79	0.94	0.74	-0.31	1.0	-0.95	-0.95	-0.95		-0.95	1.0	0.87	-0.95	0.57	-0.95	0.8	-0.2	0.69	0.72	-0.52
Ebitda	-0.9	-0.94	-0.76	-1.0	-0.74	0.24	-0.95	1.0	1.0	1.0	-0.95		-0.95	-0.96	1.0	-0.61	1.0	-0.88	0.29	-0.78	-0.75	0.72
Total Operating Expenses	0.79	0.84	0.78	0.94	0.76	-0.3	1.0	-0.95	-0.95	-0.95	1.0	-0.95		0.87	-0.95	0.62	-0.95	0.81	-0.21	0.66	0.7	-0.5
Reconciled Depreciation	0.98	1.0	0.77	0.96	0.56	0.03	0.87	-0.96	-0.96	-0.96	0.87	-0.96	0.87		-0.96	0.69	-0.96	0.96	-0.55	0.84	0.8	-0.8
Income Before Tax	-0.9	-0.94	-0.76	-1.0	-0.74	0.24	-0.95	1.0	1.0	1.0	-0.95	1.0	-0.95	-0.96		-0.6	1.0	-0.87	0.29	-0.78	-0.75	0.73
Total Other Income Expense Net	0.66	0.66	0.49	0.64	0.48	0.29	0.62	-0.61	-0.6	-0.61	0.57	-0.61	0.62	0.69	-0.6		-0.6	0.85	-0.59	0.29	0.28	-0.28
Net Income	-0.9	-0.94	-0.76	-1.0	-0.74	0.24	-0.95	1.0	1.0	1.0	-0.95	1.0	-0.95	-0.96	1.0	-0.6		-0.88	0.29	-0.78	-0.75	0.73
Income Tax Expense	0.95	0.95	0.75	0.89	0.5	0.22	0.81	-0.88	-0.88	-0.88	0.8	-0.88	0.81	0.96	-0.87	0.85	-0.88		-0.68	0.73	0.69	-0.7
Cost Of Revenue	-0.65	-0.59	-0.45	-0.31	0.26	-0.82	-0.21	0.3	0.29	0.3	-0.2	0.29	-0.21	-0.55	0.29	-0.59	0.29	-0.68		-0.51	-0.49	0.48
Interest Income	0.9	0.88	0.62	0.76	0.19	0.12	0.66	-0.78	-0.78	-0.78	0.69	-0.78	0.66	0.84	-0.78	0.29	-0.78	0.73	-0.51		0.97	-0.91
Non Operating Income Net Other	0.86	0.83	0.65	0.73	0.15	0.12	0.7	-0.75	-0.75	-0.75	0.72	-0.75	0.7	0.8	-0.75	0.28	-0.75	0.69	-0.49	0.97		-0.8
Selling And Marketing Expenses	-0.86	-0.84	-0.49	-0.73	-0.22	-0.12	-0.5	0.73	0.73	0.72	-0.52	0.72	-0.5	-0.8	0.73	-0.28	0.73	-0.7	0.48	-0.91	-0.8

Click cells to compare fundamentals

Gain Therapeutics Account Relationship Matchups

Gain Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Tax Provision	7.1K	5.4K	4.0K	93.0K	142.9K	150.0K
Net Interest Income	(20.5K)	3.6K	12.5K	375.4K	551.7K	579.3K
Depreciation And Amortization	68.3K	9.6K	15.5K	64.2K	83.6K	44.3K
Interest Expense	20.5K	189.3K	117.9K	247.4K	284.5K	298.7K
Selling General Administrative	555.2K	1.2M	6.8M	9.5M	10.8M	11.3M
Total Revenue	41.3K	28.9K	165.0K	140.1K	55.2K	82.7K
Gross Profit	41.3K	(2.2M)	(7.0M)	75.9K	(25.2K)	(26.5K)
Other Operating Expenses	2.1M	3.5M	14.0M	17.9M	22.3M	11.2M
Operating Income	(2.1M)	(3.5M)	(13.8M)	(17.8M)	(22.3M)	(21.1M)
Net Income From Continuing Ops	(2.2M)	(3.6M)	(13.9M)	(17.6M)	(22.2M)	(21.1M)
Ebit	(2.1M)	(3.5M)	(13.8M)	(17.8M)	(22.3M)	(21.1M)
Research Development	1.6M	2.3M	7.2M	8.4M	11.5M	5.8M
Ebitda	(2.0M)	(3.5M)	(13.8M)	(17.8M)	(22.2M)	(21.1M)
Total Operating Expenses	2.1M	3.5M	14.0M	17.9M	22.3M	11.2M
Reconciled Depreciation	2.6K	9.6K	15.5K	64.2K	78.1K	82.0K
Income Before Tax	(2.2M)	(3.6M)	(13.9M)	(17.5M)	(22.2M)	(21.1M)
Total Other Income Expense Net	(86.2K)	(92.8K)	(60.4K)	279.3K	64.9K	68.1K
Net Income Applicable To Common Shares	(2.2M)	(3.6M)	(13.9M)	(17.6M)	(15.8M)	(15.0M)
Net Income	(2.2M)	(3.6M)	(13.9M)	(17.6M)	(22.3M)	(21.2M)
Income Tax Expense	7.1K	5.4K	4.0K	93.0K	79.3K	83.2K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Gain Stock Analysis

When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Gain Historical Income Statement

About Gain Income Statement Analysis

Gain Therapeutics Income Statement Chart

Tax Provision

Total Revenue

Other Operating Expenses

Gain Therapeutics income statement Correlations

Gain Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Gain Therapeutics income statement Accounts

Also Currently Popular

Additional Tools for Gain Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Reconciled Depreciation	+ 1.0	Net Interest Income
Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Net Income From Continuing Ops	+ 1.0	Operating Income
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income

Net Income	- 1.0	Selling General Administrative
Income Before Tax	- 1.0	Selling General Administrative
Ebitda	- 1.0	Selling General Administrative
Ebit	- 1.0	Selling General Administrative
Net Income From Continuing Ops	- 1.0	Selling General Administrative
Operating Income	- 1.0	Selling General Administrative